 | |
| Clinical data | |
|---|---|
| ATC code | |
| Identifiers | |
| |
| CAS Number | |
| PubChemCID | |
| ChemSpider |
|
| UNII | |
| ChEBI | |
| CompTox Dashboard(EPA) | |
| ECHA InfoCard | 100.020.571 |
| Chemical and physical data | |
| Formula | C22H30O3 |
| Molar mass | 342.479 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
 N Y (what is this?) (verify) | |
Megestrol (INNTooltip International Nonproprietary Name,BANTooltip British Approved Name) is aprogestin of the17α-hydroxyprogesterone group which was, until recently, never marketed or used clinically.[1][2] It is now used for treatments ofdisease-related weight loss,endometrial cancer, andbreast cancer.[3] Itsacylated derivativemegestrol acetate is also aprogestogen, which, in contrast to megestrol itself, has been extensively used as apharmaceuticaldrug.[1][2]
As of June 2023, megestrol is being used to treat significant weight loss inHIV/AIDS patients, and as apalliative treatment ofendometrial andbreast cancers. It can be administered in both tablet and oral suspension forms, with dosages ranging from 100 mg/day to 1600 mg/day depending on the condition being treated.[3]
 | Thisdrug article relating to thegenito-urinary system is astub. You can help Wikipedia byexpanding it. |
